BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25079971)

  • 1. Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis.
    Lang K; Patel AA; Munsell M; Bookhart BK; Mody SH; Schein JR; Menzin J
    J Thromb Thrombolysis; 2015 May; 39(4):434-42. PubMed ID: 25079971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
    LaMori JC; Shoheiber O; Mody SH; Bookhart BK
    Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
    Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
    J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.
    Spyropoulos AC; Lin J
    J Manag Care Pharm; 2007; 13(6):475-86. PubMed ID: 17672809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.
    MacDougall DA; Feliu AL; Boccuzzi SJ; Lin J
    Am J Health Syst Pharm; 2006 Oct; 63(20 Suppl 6):S5-15. PubMed ID: 17032933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.
    Dasta JF; Pilon D; Mody SH; Lopatto J; Laliberté F; Germain G; Bookhart BK; Lefebvre P; Nutescu EA
    Thromb Res; 2015 Feb; 135(2):303-10. PubMed ID: 25555319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospital charges associated with "never events": comparison of anterior cervical discectomy and fusion, posterior lumbar interbody fusion, and lumbar laminectomy to total joint arthroplasty.
    Daniels AH; Kawaguchi S; Contag AG; Rastegar F; Waagmeester G; Anderson PA; Arthur M; Hart RA
    J Neurosurg Spine; 2016 Aug; 25(2):165-9. PubMed ID: 26989978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inpatient and outpatient occurrence of deep vein thrombosis and pulmonary embolism and thromboprophylaxis following selected at-risk surgeries.
    Amin AN; Lin J; Thompson S; Wiederkehr D
    Ann Pharmacother; 2011 Sep; 45(9):1045-52. PubMed ID: 21862717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of hospital readmission in patients diagnosed with DVT and PE: clinical burden of recurrent events.
    Nutescu EA; Crivera C; Schein JR; Bookhart BK
    Int J Clin Pract; 2015 Mar; 69(3):321-7. PubMed ID: 25395271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of patients with pulmonary embolism versus deep vein thrombosis: From the COMMAND VTE Registry.
    Yamashita Y; Murata K; Morimoto T; Amano H; Takase T; Hiramori S; Kim K; Oi M; Akao M; Kobayashi Y; Toyofuku M; Izumi T; Tada T; Chen PM; Tsuyuki Y; Saga S; Nishimoto Y; Sasa T; Sakamoto J; Kinoshita M; Togi K; Mabuchi H; Takabayashi K; Yoshikawa Y; Shiomi H; Kato T; Makiyama T; Ono K; Nawada R; Onodera T; Kimura T;
    Thromb Res; 2019 Dec; 184():50-57. PubMed ID: 31706068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Incidence and Economic Burden of In-Hospital Venous Thromboembolism in the United States.
    Shahi A; Chen AF; Tan TL; Maltenfort MG; Kucukdurmaz F; Parvizi J
    J Arthroplasty; 2017 Apr; 32(4):1063-1066. PubMed ID: 27866951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.
    Jiménez D; Díaz G; Marín E; Vidal R; Sueiro A; Yusen RD
    Thromb Haemost; 2006 Mar; 95(3):562-6. PubMed ID: 16525588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
    Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
    J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
    [No Abstract]   [Full Text] [Related]  

  • 17. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.
    Levitan N; Dowlati A; Remick SC; Tahsildar HI; Sivinski LD; Beyth R; Rimm AA
    Medicine (Baltimore); 1999 Sep; 78(5):285-91. PubMed ID: 10499070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of hospitalization costs for 278 venous thromboeboembolism patients with health insurance in China].
    Wu JJ; Yang L
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 45(3):437-42. PubMed ID: 23774924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.
    Ollendorf DA; Vera-Llonch M; Oster G
    Am J Health Syst Pharm; 2002 Sep; 59(18):1750-4. PubMed ID: 12298113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.